title: Current status of targeted therapies for mantle cell lymphoma.
abstract: Mantle cell lymphoma (MCL) is a type of non-Hodgkin's lymphoma (NHL) with treatment outcomes that have historically been poorer than those observed with other NHL subtypes. Patients typically present with advanced-stage disease and frequent extranodal involvement; the median age at diagnosis is >60 years. Recent improvements in progression-free and overall survival have been observed with more dose-intensive strategies, although at least half of patients diagnosed with MCL are not eligible for such treatment approaches based on age and co-morbidities. In addition, therapy options for relapsed MCL are limited. Only bortezomib is approved for treatment of relapsed MCL in the US. Development of targeted therapy approaches to minimize toxicities while preserving anti-neoplastic properties is of particular importance in MCL. Multiple ongoing studies are attempting to build on the known efficacy of bortezomib by evaluating combination regimens with other targeted agents or cytotoxic chemotherapy. The mammalian target of rapamycin (mTOR) inhibitor temsirolimus has known activity in MCL, making this an attractive class of agents for further investigation in combination regimens. Rituximab and other monoclonal antibodies are being evaluated for novel roles in MCL treatment, including as maintenance therapy. Other classes of drugs being investigated in MCL are immunomodulatory agents, inhibitors of the phosphoinositide 3-kinase/Akt and B-cell receptor signalling pathways, and inhibitors of bcl-2 and histone deacetylase. Although many of the agents appear to have modest single-agent activity, the favourable toxicity profile of many agents will make them best suited for incorporation into combination regimens.
authors.affiliation: Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705, USA. jc2@medicine.wisc.edu
authors.forename: Julie E
authors.initials: JE
authors.lastname: Chang
authors.forename: Brad S
authors.initials: BS
authors.lastname: Kahl
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy*; D058990:Molecular Targeted Therapy / Q000009:adverse effects / Q000379:methods*
chemical_list: D000970:Antineoplastic Agents
references.citation: J Immunol. 2003 Jul 1;171(1):88-95
references.pmid: 12816986
references.citation: J Clin Oncol. 2008 Sep 20;26(27):4473-9
references.pmid: 18626004
references.citation: J Clin Oncol. 2010 Jan 20;28(3):418-23
references.pmid: 20008633
references.citation: Clin Cancer Res. 2009 Feb 15;15(4):1126-32
references.pmid: 19228717
references.citation: Blood. 2005 Apr 1;105(7):2677-84
references.pmid: 15591112
references.citation: J Clin Oncol. 2005 Mar 20;23(9):1984-92
references.pmid: 15668467
references.citation: J Immunol. 2006 May 15;176(10):5715-9
references.pmid: 16670274
references.citation: Leuk Lymphoma. 2004 Dec;45(12):2445-9
references.pmid: 15621757
references.citation: Eur J Haematol. 2006 Jan;76(1):42-50
references.pmid: 16343270
references.citation: Clin Cancer Res. 2008 May 1;14(9):2756-62
references.pmid: 18451242
references.citation: J Clin Oncol. 2009 Dec 20;27(36):6101-8
references.pmid: 19917845
references.citation: Mol Immunol. 2009 Jul;46(11-12):2419-23
references.pmid: 19427037
references.citation: J Clin Oncol. 2005 Oct 1;23(28):7013-23
references.pmid: 16145068
references.citation: Blood. 2006 Nov 15;108(10):3295-301
references.pmid: 16873669
references.citation: J Clin Oncol. 2009 Feb 1;27(4):511-8
references.pmid: 19075279
references.citation: Drug Resist Updat. 2008 Feb-Apr;11(1-2):32-50
references.pmid: 18166498
references.citation: Curr Treat Options Oncol. 2006 Jul;7(4):285-94
references.pmid: 16916489
references.citation: Br J Cancer. 2002 Nov 4;87(10):1166-72
references.pmid: 12402158
references.citation: Leuk Lymphoma. 2001 Sep-Oct;42(5):1015-22
references.pmid: 11697618
references.citation: Drug Discov Today. 2010 Mar;15(5-6):243-9
references.pmid: 20116451
references.citation: Blood. 2006 Dec 15;108(13):4003-8
references.pmid: 16946304
references.citation: J Clin Oncol. 2005 Aug 10;23(23):5347-56
references.pmid: 15983389
references.citation: Lancet Oncol. 2010 Dec;11(12):1149-59
references.pmid: 21094089
references.citation: Blood. 2006 Jan 1;107(1):257-64
references.pmid: 16166592
references.citation: Blood. 2008 Feb 15;111(4):2230-7
references.pmid: 18006696
references.citation: J Clin Oncol. 2009 Aug 10;27(23):3822-9
references.pmid: 19581539
references.citation: J Clin Oncol. 1999 Feb;17(2):546-53
references.pmid: 10080598
references.citation: J Clin Oncol. 2002 Mar 1;20(5):1288-94
references.pmid: 11870171
references.citation: J Clin Oncol. 2005 Feb 1;23(4):705-11
references.pmid: 15598978
references.citation: J Clin Oncol. 2006 Oct 20;24(30):4867-74
references.pmid: 17001068
references.citation: Blood. 2008 Oct 1;112(7):2687-93
references.pmid: 18625886
references.citation: Oncology (Williston Park). 2009 Jul;23(8):683-90
references.pmid: 19711582
references.citation: Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19512-7
references.pmid: 18040043
references.citation: Blood. 2009 Dec 3;114(24):5007-15
references.pmid: 19828699
references.citation: Clin Cancer Res. 2006 Sep 1;12(17):5165-73
references.pmid: 16951235
references.citation: J Clin Oncol. 2010 Jul 20;28(21):3525-30
references.pmid: 20458041
references.citation: J Clin Oncol. 2005 May 20;23(15):3383-9
references.pmid: 15908650
references.citation: Blood. 2007 May 15;109(10):4441-9
references.pmid: 17227835
references.citation: Ann Oncol. 1995 Mar;6(3):257-62
references.pmid: 7612491
references.citation: Crit Rev Immunol. 2002;22(5-6):425-37
references.pmid: 12803319
references.citation: Lancet Oncol. 2011 May;12(5):431-40
references.pmid: 21507715
references.citation: Clin Cancer Res. 2003 Dec 15;9(17):6316-25
references.pmid: 14695130
references.citation: J Immunol. 2006 Jul 1;177(1):362-71
references.pmid: 16785532
references.citation: J Clin Oncol. 2009 Apr 1;27(10):1607-14
references.pmid: 19255334
references.citation: Cancer Sci. 2010 Jan;101(1):196-200
references.pmid: 19817748
references.citation: Leukemia. 2008 Sep;22(9):1712-20
references.pmid: 18596739
references.citation: Blood. 2000 Jul 15;96(2):393-7
references.pmid: 10887097
references.citation: J Clin Oncol. 2009 Mar 10;27(8):1209-13
references.pmid: 19188674
references.citation: Clin Cancer Res. 2010 Aug 15;16(16):4094-104
references.pmid: 20682705
references.citation: Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5291-4
references.pmid: 17875757
references.citation: Nat Rev Cancer. 2004 Apr;4(4):314-22
references.pmid: 15057291
references.citation: Cancer. 2008 Jul 1;113(1):108-16
references.pmid: 18470909
references.citation: Lancet. 2011 Jan 1;377(9759):42-51
references.pmid: 21176949
references.citation: Ann Oncol. 2008 Jul;19(7):1327-1330
references.pmid: 18349031
references.citation: Blood. 1997 Jun 1;89(11):3909-18
references.pmid: 9166827
references.citation: Nat Rev Cancer. 2006 Mar;6(3):184-92
references.pmid: 16453012
references.citation: J Clin Oncol. 2005 Sep 10;23(26):6409-14
references.pmid: 16155027
references.citation: Cancer. 2008 Aug 1;113(3):508-14
references.pmid: 18543327
references.citation: Blood. 2009 Aug 20;114(8):1469-76
references.pmid: 19556426
references.citation: Expert Opin Investig Drugs. 2002 Dec;11(12):1695-713
references.pmid: 12457432
references.citation: Leuk Lymphoma. 2010 Jul;51(7):1269-77
references.pmid: 20572799
references.citation: J Clin Oncol. 2003 May 1;21(9):1740-5
references.pmid: 12735303
references.citation: Blood. 2007 Jan 1;109(1):31-9
references.pmid: 16960145
references.citation: Oncologist. 2009;14 Suppl 2:17-29
references.pmid: 19819921
references.citation: Cancer Res. 2008 May 1;68(9):3413-20
references.pmid: 18451169
references.citation: Blood. 2011 Jan 13;117(2):591-4
references.pmid: 20959606
references.citation: Blood. 1998 Nov 15;92(10):3804-16
references.pmid: 9808574
references.citation: Br J Haematol. 2011 Oct;155(2):190-7
references.pmid: 21848883
references.citation: Crit Rev Oncol Hematol. 2011 Oct;80(1):69-86
references.pmid: 21168343
references.citation: Cancer. 1998 Feb 1;82(3):567-75
references.pmid: 9452276
references.citation: Nat Rev Cancer. 2004 May;4(5):335-48
references.pmid: 15122205
references.citation: Ann Oncol. 2007 Jan;18(1):116-121
references.pmid: 16971665
references.citation: J Clin Oncol. 2005 Jan 20;23(3):630-9
references.pmid: 15659509
references.citation: Hematology Am Soc Hematol Educ Program. 2010;2010:265-70
references.pmid: 21239804
references.citation: J Clin Oncol. 2007 Jul 20;25(21):3109-15
references.pmid: 17577020
references.citation: Lancet. 2008 Aug 9;372(9637):449-56
references.pmid: 18653228
references.citation: J Immunol. 2000 Aug 1;165(3):1300-6
references.pmid: 10903730
references.citation: Cancer. 2006 Oct 1;107(7):1542-50
references.pmid: 16948126
references.citation: N Engl J Med. 2007 May 31;356(22):2271-81
references.pmid: 17538086
references.citation: Blood. 2004 Oct 15;104(8):2269-71
references.pmid: 15166030
references.citation: Ann Oncol. 2009 Mar;20(3):520-5
references.pmid: 19074748
references.citation: Blood. 2003 Jan 15;101(2):391-8
references.pmid: 12393555
references.citation: Blood. 2007 Oct 1;110(7):2667-73
references.pmid: 17606765
references.citation: Br J Haematol. 2009 May;145(3):344-9
references.pmid: 19245430
references.citation: Blood. 2008 Feb 1;111(3):1094-100
references.pmid: 18003886
references.citation: Blood. 2008 Jun 15;111(12):5486-95
references.pmid: 18390837
references.citation: Blood. 2006 Jun 1;107(11):4540-8
references.pmid: 16497967
references.citation: J Clin Oncol. 2010 Jun 10;28(17):2853-8
references.pmid: 20439641
references.citation: J Clin Oncol. 1998 Aug;16(8):2780-95
references.pmid: 9704731
references.citation: Expert Rev Anticancer Ther. 2009 Sep;9(9):1305-16
references.pmid: 19761434
references.citation: J Clin Oncol. 2008 Oct 20;26(30):4952-7
references.pmid: 18606983
references.citation: Nat Rev Cancer. 2004 May;4(5):349-60
references.pmid: 15122206
references.citation: Blood. 2010 Aug 19;116(7):1025-34
references.pmid: 20427703
references.citation: Blood. 2010 Apr 1;115(13):2578-85
references.pmid: 19965662
references.citation: J Clin Oncol. 2009 Nov 1;27(31):5213-8
references.pmid: 19770379